GlassScriptPhysician profile
Rachel Pope
NPI 1255623658
$48,647.50
in general payments reported to CMS, 2019-2025
30 companies · $28K in 2025
The $28K reported for 2025 was more than what 98% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,546 · 2022: $3,152 · 2023: $8,707 · 2024: $6,637 · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Consulting Fee: $4,867 · Travel and Lodging: $3,742 · Food and Beverage: $2,680 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,496.50 |
| Consulting Fee | $4,867.00 |
| Travel and Lodging | $3,741.93 |
| Food and Beverage | $2,679.71 |
| Education | $163.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $32,886.91 | 2023-2025 | Veozah, Myrbetriq |
| Medical Device Business Services, INC. | $9,870.00 | 2021-2025 | Na |
| Bayer Healthcare Pharmaceuticals INC. | $2,454.00 | 2025 | |
| Synthes USA Products LLC | $1,168.74 | 2024 | |
| Kerecis Limited | $433.97 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Merck Sharp & Dohme LLC | $214.50 | 2023-2025 | Lynparza, Keytruda, Keytruda Qlex |
| Axonics, INC. | $172.81 | 2022-2023 | Axonics, Bulkamid |
| Integra Lifesciences Corporation | $151.97 | 2021 | |
| Mayne Pharma Commercial LLC | $149.98 | 2024 | |
| Coloplast Corp | $137.61 | 2025 | |
| Biotissue Holdings INC. | $123.90 | 2023 | |
| Sumitomo Pharma America, INC. | $95.82 | 2023-2025 | Gemtesa |
| Caldera Medical, INC | $84.43 | 2021 | |
| Dentsply Ih Ab | $84.22 | 2024 | Lofric |
| Janssen Biotech, INC. | $80.48 | 2025 | Erleada |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $74.60 | 2022 | |
| Abbvie INC. | $73.00 | 2022-2024 | |
| Applied Medical Resources Corporation | $66.14 | 2022 | |
| Allergan, INC. | $41.29 | 2021 | |
| Aroa Biosurgery Incorporated | $40.78 | 2023 | |
| Photocure INC | $34.90 | 2022-2024 | Cysview |
| Immunitybio, INC. | $34.62 | 2025 | |
| Teleflex LLC | $26.44 | 2024 | |
| Millicent US INC | $24.53 | 2024 | Intrarosa |
| Baxter Healthcare | $24.38 | 2023 | Tisseel |
| Urogen Pharma, INC. | $22.58 | 2025 | |
| Hologic Sales and Service, LLC | $20.84 | 2023 | Acessa Provu System, Omni Hysteroscope |
| Antares Pharma, INC. | $20.60 | 2021 | |
| Boston Scientific Corporation | $17.93 | 2024 | Spaceoar Vue System - 10ml |
| Pfizer INC. | $15.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Pope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.